The impact of additional malignancies in patients diagnosed with gastrointestinal stromal tumors

2016 ◽  
Vol 139 (8) ◽  
pp. 1744-1751 ◽  
Author(s):  
Myles J. Smith ◽  
Henry G. Smith ◽  
Alyson L. Mahar ◽  
Calvin Law ◽  
Yoo-Joung Ko
Keyword(s):  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors ◽  
The Impact

scholarly journals The Effect of Marital Status on Survival of Patients with Gastrointestinal Stromal Tumors: A SEER Database Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Wei Song ◽  
Chuan Tian
Keyword(s):  
Prognostic Factor ◽  
Marital Status ◽  
Gastrointestinal Stromal Tumors ◽  
Cox Regression ◽  
Seer Database ◽  
Cancer Specific Survival ◽  
Stromal Tumors ◽  
Kaplan Meier ◽  
Risk Of Cancer ◽  
The Impact

Background. Marital status has been reported to be a prognostic factor in multiple malignancies. However, its prognostic value on gastrointestinal stromal tumors (GISTs) have not yet been determined. The objective of the present analysis was to assess the effects of marital status on survival in patients with GISTs. Methods. The Surveillance, Epidemiology, and End Results (SEER) database was used to analyze 6195 patients who were diagnosed with GISTs from 2001 to 2014. We also use Kaplan-Meier analysis and Cox regression to analyze the impact of marital status on cancer-specific survival (CSS). Results. Patients in the married group had more frequency in white people, more high/moderate grade tumors, and were more likely to receive surgery. Widowed patients had a higher proportion of women, a greater proportion of older patients (>60 years), and more common site of the stomach. Multivariate analysis demonstrated that marital status was an independent prognostic factor for GISTs (P<0.001). Married patients had better CSS than unmarried patients (P<0.001). Subgroup analysis suggested that widowed patients had the lowest CSS compared with all other patients. Conclusions. Marital status is a prognostic factor for survival in patients with GISTs, and widowed patients are at greater risk of cancer-specific mortality.

scholarly journals Surgery Prolongs the Survival of Patients with Metastatic, Recurrent, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Response to Imatinib Mesylate Treatment: A Systematic Review and Meta-analysis

2021 ◽  
Author(s):  
Weihao Li ◽  
Jianhong Peng ◽  
Xinyue Li ◽  
Rongxin Zhang ◽  
Binyi Xiao ◽  
...  
Keyword(s):  
Imatinib Mesylate ◽  
Gastrointestinal Stromal Tumors ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Final Analysis ◽  
Cochrane Library ◽  
Stromal Tumors ◽  
Pooled Data ◽  
Surgery Group ◽  
The Impact

Abstract Background The role of surgery in patients with metastatic, recurrent or unresectable locally advanced gastrointestinal stromal tumors (GIST) who respond to imatinib mesylate (IM) treatment is still not formally defined. Therefore, we systemically searched and analyzed the available literature to evaluate the oncologic benefits of surgery in this specific population. Methods A systematic literature search of the PubMed, Embase, and Cochrane Library databases was performed to identify relevant articles on July 16, 2020. Pooled data analysis was also performed using Review Manager. Results Totally 10 studies including 1188 patients (410 patients in the surgery group and 778 patients in the no surgery group) were included in the final analysis. No significant differences in baseline clinical characteristics were found except that patients in the surgery group were significantly younger (WMD, -5.02, 95% CI, -8.38 to -1.67, P = 0.003). In the overall population, pooled data showed a significant improvement in overall survival (OS) (HR, 0.62; 95% CI, 0.53 to 0.73; P < 0.0001) and progression-free survival (PFS) (HR, 0.57; 95% CI, 0.44 to 0.72; P < 0.0001) with surgery. In the subgroup analysis, the impact of surgery on patient response to IM treatment was further confirmed (OS: HR, 0.67; 95% CI, 0.55 to 0.81; P < 0.0001; PFS: HR, 0.62; 95% CI, 0.46 to 0.82; P = 0.009). Conclusions Surgery prolongs the OS and PFS of patients with metastatic, recurrent, or unresectable locally advanced GIST who respond to IM treatment. Future prospective, multicenter RCTs are warranted.

Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors (GIST): A retrospective, multicenter, real-world study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e23521-e23521
Author(s):  
Margherita Nannini ◽  
Alessandro Rizzo ◽  
Maria Concetta Nigro ◽  
Bruno Vincenzi ◽  
Alessandro Mazzocca ◽  
...  
Keyword(s):  
Overall Survival ◽  
Clinical Practice ◽  
Real World ◽  
Gastrointestinal Stromal Tumors ◽  
Treatment Plan ◽  
Progression Free Survival ◽  
Term Therapy ◽  
Free Survival ◽  
Stromal Tumors ◽  
The Impact

e23521 Background: Regorafenib (REG) is a multikinase inhibitor approved as third-line treatment in gastrointestinal stromal tumors (GIST). Although its proven activity, REG can present a relevant adverse profile which often leads to treatment modifications and transient or permanent discontinuation; thus, in clinical practice physicians usually adopt various dosing and interval schedules to counteract REG-related adverse events (AEs) and avoid treatment interruption. The aim of this real-world study was to investigate the efficacy and safety of personalized schedules of REG in metastatic GIST patients, in comparison with the standard schedule (160 mg daily, 3-weeks-on, 1-week-off schedule). Methods: Institutional registries across seven Italian reference centers were retrospectively reviewed and data of interest retrieved to identify GIST patients who had received REG from February 2013 to January 2021. The primary endpoint was Progression-Free Survival (PFS), with Overall Survival (OS) also assessed as secondary endpoint. The Kaplan-Meier method was used to estimate survival and the log-rank test to make comparisons. The impact of variables on survival was assessed through univariate and multivariate analysis. Results: A total of 152 GIST patients (82 male and 70 female) were included and split in two groups on the basis of the REG treatment plan received (standard vs personalized). Among the 103 patients for whom the treatment was personalized (38 since the beginning and 65 during the treatment course), the main strategies adopted were the following: 120 mg/day d1-21 e28 (n = 56; 54.4%); 80 mg/day d1-21 e28 (n = 22; 21.4%); 160 mg/day d1-5 e7 (n = 13; 12.6%). At a median follow-up of 36.5 months, median Overall Survival (OS) was 16.6 months (95% CI 14.1-21.8) and 20.5 months (95% CI 15.0-25.4) in the standard-dose and the personalized schedule groups, respectively (HR 0.75; 95% CI 0.49-1.22; p = 0.16). Median Progression-Free Survival (PFS) was 5.6 months (95% CI 3.3-not reached) and 9.7 months (95% CI 7.9-14.5) in the same groups (HR 0.51; 95% CI 0.34-0.75; p = 0.00052). Conclusions: Despite the expected limits of a retrospective analysis, we confirm that REG personalized schedules are commonly adopted in everyday clinical practice of high-volume GIST expert centers and correlate with significant improvement of therapeutic outcomes. Based on these results, REG treatment optimization in GIST patients may represent the best strategy to maximize long-term therapy, preserving tolerability and quality of life.

The impact of c-kit mutations on histomorphological risk assessment of gastrointestinal stromal tumors

2007 ◽  
Vol 39 (1) ◽  
pp. 45-53 ◽  
Author(s):  
M. Koelz ◽  
N. Wick ◽  
T. Winkler ◽  
F. Längle ◽  
F. Wrba
Keyword(s):  
Risk Assessment ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors ◽  
The Impact

The Impact of Imatinib on Survival and Treatment Trends for Small Bowel and Colorectal Gastrointestinal Stromal Tumors

2019 ◽  
Vol 24 (1) ◽  
pp. 98-108 ◽  
Author(s):  
Hamda Almaazmi ◽  
Miloslawa Stem ◽  
Brian D. Lo ◽  
James P. Taylor ◽  
Sandy H. Fang ◽  
...  
Keyword(s):  
Small Bowel ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors ◽  
Treatment Trends ◽  
The Impact

Surgical management of gastrointestinal stromal tumors: A single institution 31 — Year experience

2001 ◽  
Vol 120 (5) ◽  
pp. A401-A401 ◽  
Author(s):  
D EFRON ◽  
K LILLEMOE ◽  
J CAMERON ◽  
S TIERNEY ◽  
S ABRAHAM ◽  
...  
Keyword(s):  
Surgical Management ◽  
Gastrointestinal Stromal Tumors ◽  
Single Institution ◽  
Stromal Tumors
Sign in / Sign up

Export Citation Format

Share Document